Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia
To assess the 1-week effects and safety of esketamine in combination with pregabalin and duloxetine to relieve pain in patients with postherpetic Neuralgia(PHN).
| Condition(s) | Postherpetic Neuralgia |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | To assess the 1-week effects and safety of esketamine in combination with pregabalin and duloxetine to relieve pain in patients with postherpetic Neuralgia(PHN). |
| Who can participate | Inclusion Criteria: 1. Ages more than 18 years; 2. Pain present for more than 3 months after healing of a herpes zoster skin rash; 3. Has an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0= no pain, 10= worst possible pain)； 4. Failed to respond to or tolerate the effective dose of pregabalin monotherapy. Exclusion Criteria: 1. Obstructive sleep apnoea syndrome; 2. Those who receive interventional treatments; 3. A history of systemic immune diseases, organ transplantation, or cancers; 4. A history of severe cardiopulmonary, hepatic or renal dysfunction; 5. A history of schizophrenia, epilepsy, or myasthenia gravis, delirium; 6. Currently using monoamine oxidase inhibitors (MAOIs); 7. Having untreated angle-closure glaucoma; 8. Those suffering from increased intracranial |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Beijing Tiantan Hospital |
| Locations | Beijing, Beijing Municipality, China |
| Start date | 2025-04-01 |
| NCT ID | NCT06896994 |
| Official listing | https://clinicaltrials.gov/study/NCT06896994 |